PHARMAC
TE PĀTAKA WHAIORANGA

Specialist Advisory Committees
Objective advice to Pharmac
www.pharmac.govt.nz

Cancer Treatments Advisory Committee Provisional recommendations 6 November 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.
More information about provisional recommendations is on Pharmac's website

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Ribociclib for the adjuvant treatment of HR positive/HER-2 negative early breast cancer, within the context of treatments for malignancy, subject to Special Authority criteria	*High priority
Cemiplimab for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, that is ineligible for curative surgery or radiation, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Pembrolizumab for the treatment of resectable, locally advanced squamous cell carcinoma of the head and neck, with a CPS ≥10, within the context of treatments for malignancy, subject to Special Authority criteria	Low priority
Mogamulizumab for the treatment of relapsed/refractory Sézary syndrome and stage III-IV mycosis fungoides with erythrodermic disease, within the context of treatments for malignancy, subject to Special Authority criteria	High priority

*Recommendation amended following Matters Arising discussion.

More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website here.

Released 12 November 2026